Drug Pricing Investigation: Celgene and Bristol Myers Squibb--Revlimid
Loading...
Serial Number
Levin Center Identifier
Document Date
2020-09-30
Report Length
45 pages
Policy Agendas Project Major Code
Policy Agendas Project Minor Code
Additional, Minority, Dissenting Views
Report Type
Found Using Methodology
Yes
Committee(s)
Subcommittee(s)
Commission(s)
Idependent Author(s)
Brief Executive Summary
The Committee on Oversight and Reform examines the pricing practices of Celgene Corporation and Bristol Myers Squibb Company concerning Revlimid, a vital drug for treating multiple myeloma and various cancers. The report, based on over 50,000 pages of internal communications from 2009 to the present, primarily focuses on Celgene's pricing practices before its acquisition by Bristol Myers Squibb and provides insights into Bristol Myers Squibb's post-acquisition increases. The report underscores the need for structural reforms, such as Medicare negotiation, to address the ongoing issue of escalating drug prices, making critical medications unaffordable for many Americans.